A multicenter, randomized, double-blind, placebo parallel controlled clinical study of the efficacy and safety of TCM acupoint application in COVID-19 (mild, common type) in adult patients with fever

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200067178

Enrollment

Unknown

Registered

2022-12-28

Start date

2022-12-28

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (mild, common type) in adults with fever

Interventions

Treatment group:Traditional Chinese medicine acupoint application+Fuzheng Jiebiao formula

Control group:Traditional Chinese medicine acupoint application placebo+Fuzheng Jiebiao formula

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria for COVID-19; Clinical classification is light, ordinary type; The first onset of symptoms (or confirmed disease) to the random medication is not more than 48h, and the treatment has not been conducted; Body temperature: 37.3?; Age: 18-65 years old, gender is unlimited; They voluntarily participate in this clinical trial, gave informed consent and signed the informed consent form.

Exclusion criteria

Exclusion criteria: Bacteria, fungi and other infections other than novel coronavirus infection; Combined with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney, hematopoietic and endocrine system or immune system diseases (the upper limit of liver function ALT and AST> normal reference value, the upper limit of Scr> normal reference value, poor blood glucose control); Mental retardation, mental disorders; Planned pregnancy, pregnancy, lactation women and during the trial; Allergy constitution or allergy to the drug ingredients and excipients of this test; Participated in other clinical trials in the recent 1 month; The Investigator does not considered appropriate to participate in this clinical trial.

Design outcomes

Primary

Measure	Time frame
Complete antipyretic time (hours);	—

Secondary

Measure	Time frame
Onset time of antipyretic effect (hours);Utilization rate and per capita dose of emergency antipyretic drugs (acetaminophen);Change from baseline in individual symptom scores on days 4 and 6 after treatment;	—

Countries

China

Contacts

Public ContactQi wen sheng

Guang 'anmen Hospital, China Academy of Chinese Medical Sciences

qwsqws@sohu.com13671039118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026